Sanofi (SNYNF)
| Previous close | 92.76 |
| Open | 94.05 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 94.00 - 94.05 |
| 52-week range | 86.12 - 114.90 |
| Volume | |
| Avg. volume | 8,606 |
| Market cap | 117.866B |
| Beta (5Y monthly) | 0.46 |
| PE ratio (TTM) | 11.94 |
| EPS (TTM) | 7.87 |
| Earnings date | N/A |
| Forward dividend & yield | 3.81 (4.05%) |
| Ex-dividend date | 30 May 2023 |
| 1y target est | N/A |
Business WireTeva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
PARSIPPANY, N.J., November 30, 2023--Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today closing of its collaboration deal to co-develop and co-commercialize asset TEV ‘574 with Sanofi (EURONEXT: SAN and NASDAQ: SNY). TEV '574 is currently in Phase 2b clinical trials for the treatment of ulcerative colitis and Crohn's disease, two types of inflammatory bowel disease.
Motley Fool2 Biotech Stocks You Can Buy and Hold for the Next Decade
These stocks aren't popular on the market right now, but investors shouldn't let that scare them off.
- Reuters
UPDATE 2-White House urges RSV immunization makers to meet demand
Senior Biden administration officials met with the makers of RSV immunizations for children this week to underscore the need for manufacturers such as Sanofi and AstraZeneca to urgently meet demand as winter approaches, the White House said on Tuesday. At a meeting at the White House on Monday, officials and manufacturers also agreed to plan now to meet next year's demand for the immunizations targeting respiratory syncytial virus, which generally causes mild, cold-like symptoms but can develop into severe illness in infants and older adults.
